Cellectar's iopofosine i-131 exhibits signals of efficacy in phase i study for pediatric brain and solid tumors

Florham park, n.j., nov. 16, 2021 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that patients in a phase 1 study of iopofosine i-131 (“iopofosine”) in children and adolescents with relapsed and refractory high grade gliomas (hggs) and soft tissue sarcomas, exhibited positive changes in various tumor parameters. the phase 1 study is an international, open-label, dose escalation, safety study of iopofosine in children and adolescents with relapsed or refractory cancers, specifically hggs, high risk neuroblastoma and select soft tissue sarcomas.
CLRB Ratings Summary
CLRB Quant Ranking